AIMS AMP Capital Industrial REIT, Saizen REIT, Genting SP, China Hongxing, Healthway Medical and Golden Agriculture.

There is much talk about the military confrontation in the Korean peninsula which took place today. Could this be the reason why the STI sank 2%? Fear is in the air?

Seoul (The Korea Herald/ANN) - North Korea fired dozens of coastal artillery shells, some of which fell on the South's Yeonpyaong Island near the tense western inter-Korean border, the Joint Chiefs of Staff said Tuesday.

"The North fired dozens of artillery rounds from its Gaemeori western coastal artillery base at 14:34 p.m. In response to the military provocations, we fired back dozens of rounds with K9 self-propelled howitzers," JCS spokesman Col. Lee Bung-woo told reporters.

In the artillery firing, one soldier was killed and four marine solider were seriously injured. The military was trying to evacuate civilians on the island near the border. Several civilians were reported to have suffered injuries.

Read full story here.

STI at new November low, off 1.4%; 3,119 support
Tuesday, 23 November 2010

© 2010 - The Edge Singapore

I would keep calm and question how would the events affect my investments. As far as I could see, my investments are relatively unscathed. If there should be some irrational selling down, I could buy more. Let us look at some counters:


AIMS AMP Capital Industrial REIT
The recent buying up of units in this REIT at 22.5c and 23c evaporated today. On 25 Oct, I mentioned that "A reader asked if I managed to get more at 22c today. No, I didn't. I am waiting at 21.5c." Today, I got what I have been waiting for. My overnight buy queue at 21.5c was filled.

Fundamentally, there is no reason for a weakening of price here. Technically, it could weaken and I decided to wait and it paid off. Now, could it weaken further and I know for a fact that someone in LP's infamous cbox is waiting to buy at 1 bid lower than my purchase price today.

21c looks like a many times tested resistance of an earlier base formation and this could be a strong support if price ever goes that low. I would buy more then. In fact, I am already in the buy queue. The MACD is testing its own trendline support and I would be surprised if price goes much lower.

Related post:
AIMS AMP Capital Industrial REIT: Accumulation price?

Saizen REIT
This REIT's unit price has been showing some resilience lately which leads me to believe that most of the people who would sell at 15.5c have sold. Despite a rather large sell down of more than 5,000 lots today, unit price remained at 16c. I believe that is a sign of strength.

Looking at the chart, it seems that 16.5c is the upper limit of the Bollinger bands and at 16c, this REIT is trading above all the daily MAs except the 200dMA. I like the rising MACD. All the daily MAs are coming together, bunching together, creating much tension. One day, the spring would have to uncoil.

Genting SP
A friend has money tied up here and I am sure quite a few readers too including someone who wrote recently that he gave up on Saizen REIT and shifted his money into Genting SP instead. On 18 Nov, I mentioned that "If price does not recapture the 50dMA as support, immediate support is at $2 with the next support after that at $1.85."

The support at $2 cracked today and it looked, for a few moments, as if it could just cling on but the bears proved too strong and a wickless black candle was formed as price closed at $1.95 on high volume. $2 could now be resistance. The gap down on 12 Nov was indeed a bad omen.

With the 20dMA turning down and the MACD dipping into negative territory, we could see a further weakening of price here. $1.85 as a support could be tested in due course. Since peaking on 9 Nov, OBV has been in decline which suggests that distribution is ongoing. This could exert further downward pressure on the share price.

Genting Singapore off 2.9%; Support at $1.85
Tuesday, 23 November 2010

© 2010 - The Edge Singapore

China Hongxing
The support provided by the 200dMA has been taken out and price closed at 14.5c. If 14.5c fails to hold, we could see support at 13c tested in due course. 13c was the neckline of the double bottom formed in June/July and should be a stronger support.

MFI could be testing its uptrend support soon. RSI and Stochastics are both in oversold region. However, the MACD histogram's buy signal has been negated.  It would be prudent to wait for clearer signs of a reversal before wading into a long position here, especially with the support at 200dMA compromised.

Related post:
China Hongxing: Testing support.

Healthway Medical
Technically, the picture remains largely the same. However, the buy signal on the MACD histogram has been negated. Volume remains low and there was some selling down at 15c, the floor identified earlier.

Immediate resistance is at 15.5c which is also where the 20dMA is approximating. The jury is still out on this one.

Related post:
Healthway Medical: Prime for a rebound?

Golden Agriculture
On 18 Nov, I said "I still see a negative divergence between price and volume. The MACD has completed a bearish crossover with the signal line but being in positive territory, it suggests that the retreat in price could just be a correction. In such a case, we could see price weakening further to 65c, the next major support, if the support at 70c fails to hold up."

Support at 70c was taken out convincingly today. The MACD continues to decline, pulling away below the signal line although still in positive territory. MFI and RSI have been forming lower highs.  All suggest that positive momentum is declining. 65c support could be tested sooner rather than later. Buy at 65c? As a hedge, sure. If 65c breaks, the next support is at 61c.

Healthway Medical: Prime for a rebound?

Although I would not buy more Healthway Medical shares based on its current fundamentals, technically, it looks like it could be an interesting trade.

On 25 Oct, I mentioned that "Two identical dojis formed one after another. One today and one in the previous session. Both closed at 15.5c. Both with a low of 15c. It would seem that Healthway Medical's share price has found a floor at 15c."  Read blog post here.

15c is being tested once again as support. This is the fourth session in a row and volume has been declining.  The 20dMA has stopped declining and has flatlined. Price has stopped moving downwards in recent sessions. The floor at 15c has gained in strength.

Look at the MACD and we see that it seems to be forming a higher low. The MACD histogram has turned green, a buy signal. The MACD forms a positive divergence with the decline in share price. This is a suggestion that we could be seeing a reversal soon. Also, Stochastics is oversold and we could see a bullish crossover soon.

In the event of a rebound in price, we could have the formation of a double bottom with the neckline at 16.5c. If the double bottom is valid in such an instance, the eventual target price is 18c which would break the counter out of the down trending channel.

With lacklustre fundamentals, this would purely be a trade.

Related post:
Healthway Medical: 3Q 2010 results.

Golden Agri, Kencana Agri, Healthway Medical and Genting SP.

On 12 Nov, I mentioned that Golden Agriculture could see its support at 70c tested sooner than later. That support was tested today. Its share price bounced off the support and closed at 72c, ending the session 1c lower.

I still see a negative divergence between price and volume. The MACD has completed a bearish crossover with the signal line but being in positive territory, it suggests that the retreat in price could just be a correction. In such a case, we could see price weakening further to 65c, the next major support, if the support at 70c fails to hold up.

Singapore palm stocks hurt by China price controls. Statement from China’s State Council Wednesday says Beijing will seek to tame rising food, energy prices. “We view the price control guidelines by the Chinese government as short-term negative for CPO prices as they may weaken import demand and prompt traders to liquidate their speculative positions,” says CIMB.     
Thursday, 18 November 2010

© 2010 - The Edge Singapore

On 22 Oct, I mentioned that I was wary of Kencana Agriculture because its chart "seems to display classic signs of negative divergence between price and volume, price and MACD, price and MFI as well as price and RSI.  The shorter term 20dMA seems to be flattening."

This picture has hardly changed as its price declined to 42c, the support provided by the 20dMA, on relatively low volume. This was after three attempts to break resistance at 45c without success. I could be wrong but we might be seeing the formation of a rising wedge. If such a pattern is valid, the downside target could be at least 39c, which also seems to be a rather strong support.

On 13 Nov, I mentioned that "With the MACD, MFI and RSI all in their respective downtrends, a retest of the support at 15c is rather likely" for Healthway Medical. The counter ended the session at 15c today. The down channel's support in the next few sessions is probably at 14.5c and we could see this tested if the support at 15c fails. I still feel that 15c is a relatively strong support and if it holds, we could see the formation of a double bottom.

However, with the MACD having completed another bearish crossover with the signal line in negative territory and without any sign of a positive divergence, it could be rather risky to buy in at this stage. The downtrend might have to run its course.

Genting SP's fortunes have taken a turn for the worse. On 12 Nov, I mentioned that "If the price starts at $2.18 or higher in the next session and manages to break resistance at $2.21 which is the 50% Fibo line as well as the 20dMA, we could have a recovery. Having said this, the MACD has been moving lower as price moved higher, presenting an obvious picture of negative divergence. I would treat any rebound as a chance to reduce exposure."

Well, price started at $2.14 in the next session and closed lower, forming a black candle that almost completely engulfed the white spinning top. Closing at $2.05 today, it has gone below the support provided by the 50dMA. The counter had not traded below the 50dMA in many months.

The negative divergence between price and the MACD is playing out. With the MACD approaching zero, momentum could quickly turn negative as the lower highs on the RSI suggest weakening buying momentum. If price does not recapture the 50dMA as support, immediate support is at $2 with the next support after that at $1.85.

Macquarie cuts Genting Singapore to Underperform.  Macquarie downgrades Genting Singapore to Underperform from Neutral; “we believe the current consensus expectations for Genting Singapore are overly aggressive. In our view, they do not capture the risk of competition from Marina Bay Sands, rising political risk and limited impact from junket approvals.”      
Thursday, 18 November 2010

© 2010 - The Edge Singapore

Related posts:
Saizen REIT, First REIT, Golden Agriculture, Genting SP.
Healthway Medical: 3Q 2010 results.

Healthway Medical: 3Q 2010 results.

Healthway Medical's results came in rather weak, as expected:

1.  Revenue declined 6.2% in Q3 compared to the same period last year.  For the first 9 months, revenue declined 8.3% compared to the same period last year.

2. Staff cost increased 19.2% in Q3 compared to the same period last year.

3. Profit before income tax decreased 87.3% to $568k in Q3 compared to the same period last year.

4. Cash flow from operations is negative for the quarter at -$1.278m.

5. EPS for the quarter is 0.01c, remaining the same as the last quarter but down from 0.29c in the same quarter last year.

See results here.

We are still in the tunnel but do we see a tiny glow at the end of the tunnel?

A. Although revenue declined 6.2% compared to the same period last year, this is a smaller decline compared to Q2's decline of 12.3%. 

B. Staff cost increase of 19.2% is also smaller than Q2's 22.9%. 

C. Profit before income tax in Q2 was only $165k. So, Q3's $568k is an improvement. 

D. Cash flow from operations in Q2 was a negative $2.3m compared to a smaller negative $1.278m in Q3. 

Perhaps, points C and D are the most important indicators that things could be stabilising. However, it is still too early to say for sure.

Having said this, the proposed diversification could throw a spanner in the works. One could only hope that Healthway Medical is not biting off more than it could chew.

On 25 Oct, I suggested that Healthway Medical's share price could have found a floor at 15c. I also mentioned that any rebound would be a good chance for stale bulls to reduce exposure. 17c was never hit as the rebound in price went as high as 16.5c before declining again.

The last session saw Healthway Medical closing at 15.5c. With the MACD, MFI and RSI all in their respective downtrends, a retest of the support at 15c is rather likely. Consolation? Volume has been declining in the last few sessions. So, we could have a soft landing.

Related posts:
Healthway Medical: Second quarter results.
Healthway Medical: Business diversification.
Healthway Medical: A floor at 15c?

Healthway Medical: A floor at 15c?

On 20 Oct, I mentioned that "A gravestone doji formed today as price closed at 15.5c.  As the MFI is in very oversold condition, price could experience a brief rebound and it might be a good chance for stale bulls to lighten their long positions, if any. Strong resistance could be expected at 17c.  This is where we find the 200dMA and it is also where the falling 20d and 50d MAs would be approximating soon."

Two identical dojis formed one after another. One today and one in the previous session. Both closed at 15.5c. Both with a low of 15c. It would seem that Healthway Medical's share price has found a floor at 15c. The volume today was much lower than that of the previous session. This coupled with how dojis suggest indecision indicates a reduction in selling pressure which could help lay the foundation for a rebound or reversal. Indecision in a downtrend is good news for bulls.

The MFI is deep in oversold territory. The RSI is also in oversold territory. The OBV has gone flat, suggesting a respite from distribution activities. Could this be a false calm? Personally, I do not think that the downtrend has played out its full potential.  The lower highs on the MFI and RSI suggest negative demand and momentum and the price action of the counter is obviously caught in a down channel but it is now possibly at channel support. 

Therefore, a rebound to 17c remains probable and it still looks like it would be a good chance for stale bulls to lighten their positions in such an instance.

Related post:
Healthway Medical: Business diversification.

Healthway Medical: Business diversification.

I received a circular from Healthway Medical. This is in respect to a proposed business diversification.  Diversification? Aren't they having enough trouble trying to keep their numbers from worsening? Well, maybe, I should not jump to conclusions. Let us take a look at what is happening.

A new company, Healthway Medical Development (Pte) Limited was set up on 22 Sep 2010 as an investment holding company. This joint venture company in which Healthway Medical holds a 25% interest, hopes to "capitalise on the numerous real estate opportunities in the region, in particular the PRC, by tapping on the Medical Development Business to develop real estate projects with medical and healthcare facilities with the aim of accessing new and emerging private healthcare services markets." (on page 9 of circular)

Honestly, this sounds attractive. Any risks? Just as in its proposal to expand its business into the PRC, Healthway Medical listed the risks involved in the proposed business diversification: a total of 12 points (3.4.1 to 3.4.12, pages 13 to 17)! It seems to me that the company is taking on too much risk.

Although it is stated that this proposed business diversification has no significant financial impact on Healthway Medical's NTA per share or EPS for 2010, it was further stated that "should there be any material impact.... for FY2011, the company will make the necessary announcements at the appropriate time."  Has this been deliberately left vague? I do not appreciate this.

I feel that Healthway Medical's management have their hands full. The numbers in the last two quarters have been disappointing, to put it diplomatically. Could this proposed business diversification put further stress on resources which could already be spread thin? If Healthway Medical's share price is anything to go by, its recent weakness hints that I am not the only shareholder who is unimpressed by its performance.

A gravestone doji formed today as price closed at 15.5c.  As the MFI is in very oversold condition, price could experience a brief rebound and it might be a good chance for stale bulls to lighten their long positions, if any. Strong resistance could be expected at 17c.  This is where we find the 200dMA and it is also where the falling 20d and 50d MAs would be approximating soon.

Related post:
Healthway Medical: Second quarter results.
Healthway Medical: Testing 16c support.

Healthway Medical: Testing 16c support.

It is quite clear on the OBV that Healthway Medical has experienced three continuous days of distribution. Volume today was the highest of the last three sessions as price closed at 16c, an important support level identified earlier.

On 14 Oct, I mentioned that "16c is likely to be psychologically important as a support.  So, if it could hold up, it could provide the base for a rebound" and "if the support at 16c breaks, the uptrend is well and truly over.  We could witness a massive selling down to 14c then (the 138.2% Fibo line), followed by 13c (the 161.8% Fibo line).  So, all eyes would be on 16c."

With the lower highs on the MFI and RSI suggesting weakening demand and buying momentum, it is likely that we would see price weakening further.  The chances of a rebound look poor especially when the weakening share price is accompanied by higher volume. The negative divergence between the uptrend in price and the downtrend in the MACD has yet to play out in full.

Keep an eye on 16c and if it breaks on high volume, we could see 14c tested as support sooner than later.  Any rebound in price from the current level is likely to be met with strong resistance at 17c, formerly a strong support and it is also where the merged 20d and 50d MAs are declining to.

Related post:
Healthway Medical: Uptrend threatened.

Healthway Medical: Uptrend threatened.

On 11 Aug, I blogged about how Healthway Medical's support at 18.5c had been compromised and that price could go lower. I said that "It is likely that 17c could be tested as a support sooner than later".  Then, for a few days in late August and early September, price actually sank below 17c before recovering.

Today, the support at 17c crumbled on high volume.  That 17c was taken out when it is where the rising 200dMA is approximating is very bearish since the 200dMA is supposed to be a rather strong support. The last time this happened was in the second half of May this year but price rapidly recovered.  How high are the chances of such a recovery this time round?

Take note that the volume today was very much higher than back in May as the counter was sold down.  Back in May, the MACD was also poised to do a bullish crossover with the signal line while, this time round, it is dipping into negative territory. Lower highs spotted on the MFI and RSI, suggesting a weakening demand and slowing buying momentum.

Drawing a trendline support connecting the lows of 30 Dec 09 and 25 May 10, we see this support approximating 16c which happens to be a many times tested support from March to April this year.  16c is likely to be psychologically important as a support.  So, if it could hold up, it could provide the base for a rebound.

If the support at 16c breaks, the uptrend is well and truly over.  We could witness a massive selling down to 14c then (the 138.2% Fibo line), followed by 13c (the 161.8% Fibo line).  So, all eyes would be on 16c.

I have a very small position in Healthway Medical left which consists of rights shares and scrip dividends, average cost should be in the region of 12c, having divested >95% of my investment in the company earlier this year.  Good luck to all shareholders.

Singapore to allow stronger currency; economy shrinks: Update
Thursday, 14 October 2010

© 2010 - The Edge Singapore

Related posts:
Replies from AK71: Entry price for Healthway Medical.

Healthway Medical: 20c target.

Standard Chartered has suggested a target price of 20c for Healthway Medical. They arrived at this target price after highlighting a slew of difficulties the company faces:

1. Opening chain of clinics in China and setting up specialist center in Singapore are facing challenges in execution.

2. The group has not delivered good execution in its specialist services in the past and has limited experience of organic expansion.

3. Mass exodus of prominent specialist doctors from Healthway’s employment is also troublesome. 

4. Cost pressure mounting due to aggressive expansion.

I am almost 100% divested and I am still waiting for its share price to fall to a more reasonable level before I load up once more because if the management does deliver on its expansion plans, the company's share price would fly. At the current price, valuation is simply astronomical.

Standard Chartered's target price of 20c implies a PE of 36x!  This is almost as ridiculous as Q&M Dental Group's valuation when they first listed!  Please bear in mind that my considerations here are based on FA.  There is no accounting for sentiments.

Related post:
Healthway Medical: Second quarter results.

Healthway Medical: Up or down?

Price hit 16c on 31 Aug.  That was exactly on the rising 200dMA.  Today, the counter hit a high of 17.5c.  Technically, 17.5c is a formidable resistance level as it is a many times tested resistance and it is also where we find the declining 20dMA and the flat 100dMA.  Healthway Medical is at a critical crossroads, it would seem.

Looking at the 20dMA, there is no doubt that the counter is in a downtrend in the short term. With the 50dMA declining as well and the 100dMA flatlined, the short term picture is not encouraging.  However, the 200dMA is still rising and if it holds, Healthway Medical could just be going through a period of consolidation.

Today's upward movement in price is probably in response to the oversold situation as suggested by the RSI which has risen out of the oversold territory. The MFI, which has been rising since 18 Aug, signalling a return of demand, however weak, is testing the downtrend resistance.  If it breaks this in the next session, it would provide some much needed momentum to help push price higher.

The MACD, although still declining in negative territory, is seeing its distance with the signal line narrowing and we could be seeing the early stages of a bullish crossover. Remember, TA is about probabilities, not absolutes. Punters could make some nice gains here if everything pans out nicely.

Related post:
Healthway Medical: A low of 16c.

Healthway Medical: A low of 16c.

On 17 August, I mentioned that "there is a chance price could decline further.  If it happens, the next support is at 16c." Price touched a low of 16c today on moderate volume.  16c is also where we find the rising 200dMA today. Could this support hold?

The MFI has formed lower highs which suggests weakening demand but it recently emerged from the oversold territory which suggests the return of some demand, although weak.  The OBV does not show any drastic distribution activity while the RSI continues to decline in oversold territory, suggesting that the selling might be overdone.  Lacking in positive catalyst, this counter's price could, however, trade lower.

Taking a look at the weekly chart, we see the 50dMA at 15.5c and this would be a stronger support.

Related post:
Healthway Medical: 17c support.

Healthway Medical: 17c support.

Some large transactions sold down shares of Healthway Medical at 17c today.  Volume, although higher, is not very much so.  Would the selling pressure continue? Where is the next support?

The MACD is plunging into negative territory, widening its distance from the signal line as it does so.  The momentum has clearly turned negative. With the lower highs we see in the MFI, it is obvious that demand is weakening.  OBV which has been sloping downwards gently took a bigger dip today, suggesting consistent distribution which accelerated today.

For sure, there is a chance price could decline further.  If it happens, the next support is at 16c, a many times tested support level in April. Given Healthway Medical's fundamentals, I feel that it is expensive even at 16c but we might see momentum oscillators entering oversold territories by then and that could bring about a brief rebound. I would pay attention to the volume as price declines.

Related post:
Healthway Medical: Second quarter results.

Healthway Medical: Second quarter results.

Healthway Medical announced that it has entered into agreements with twelve (12) medical and dental centres in Shanghai and Hangzhou.  To operate and manage these facilities, an investment of RMB38m (or S$7.6m) is required over a period of three months. They hope to increase the number of facilities under management to more than twenty by end of this year.

At the same time, Healthway Medical also released their second quarter results and the numbers look bad.

1. Revenue compared to the same period last year has tumbled 12.3% from S$24.45m to S$21.44m.  This is worse than the first quarter when the revenue declined 6.3% compared to the same period a year ago.

2. Staff cost increased 22.9% which suggests that Healthway Medical is paying a lot more now to retain or to recruit staff.  In terms of absolute dollars, the increase from S$10.75m to S$13.2m is no small change.

3. Profit before income tax is an insignificant S$165k compared to S$5.23m in the same period last year.  This is much worse than the first quarter profit of S$1.4m.

4. Cash flow from operations is a negative S$2.3m compared to a positive S$4.05m in the same period last year.  However, it is an improvement over a negative S$4.94m in the last quarter.

5. Cash flow from financing activities is still a positive S$18.79m and the company has S$32.6m in bank deposits.

6. EPS for the quarter is 0.01c, down from 0.32c in the same quarter last year and down from 0.09c in the last quarter.

Fundamentally, Healthway Medical's numbers in the first quarter were relatively bad but they are now worse.  See second quarter statements here.

On 16 May, I blogged about Healthway Medical's first quarter results.  I said: "As an investor, to be prudent, I would continue to wait for greater clarity on whether higher earnings would follow, maintaining that the share price at current level does not offer good value."  This opinion has not changed.

Although Healthway Medical has taken another important step in its expansion plans in China, risks still exist and it remains to be seen if the management is able to execute its plans successfully and deliver value to shareholders.  With weakening revenue and rising costs at home and possible teething problems in China, investing in Healthway Medical at the current price is not for the faint hearted.

On 11 Aug, I blogged about how Healthway Medical's support at 18.5c has been compromised and that price could go lower. It is likely that 17c could be tested as a support sooner than later.

Related post:
Healthway Medical: A weak first quarter.
Healthway Medical: Support compromised.

Healthway Medical: Support compromised.

18.5c support which has stayed strong since early July was compromised today as price touched a low of 18c before closing at 18.5c.

The MACD continues to decline towards zero.  MFI's lower high shows a sustained reduction in demand. OBV shows some distribution activity.  Nothing too alarming.  However, without any high volume buy ups, price could drift lower.  Price is now below the 20d and 50d MAs. Next level of support is at 17c.

A quick check of the weekly chart shows that the 20wMA approximates 17c, lending strength to the idea that this could be a strong support. However, it is also obvious from the chart that price bounced off the 50wMA before heading higher in recent past.  With the MACD about to do a bearish crossover with the signal line, the possibility of price going lower cannot be discounted.

Healthway Medical: Underlying strength.

The sell signal on the MACD in the last session was negated today. In fact, the MACD seems poised to do a bullish crossover with the signal line in positive territory.

The rising MFI shows unabating demand. OBV shows gradual accumulation. 18.5c has been established as immediate support.

The rising 50dMA seems to be on course to hit 18.5c soon.  Could this push the price of Healthway Medical's shares up at the same time?

Volume has been declining as price settled into a tight range of 18.5c to 19.5c. There were two sessions in which volume spiked but price was unable to break past 19.5c.  This shows that there are still sellers out there.  However, with the OBV gradually higher, the sellers might be thinning as more accumulate shares in the company.

Technically, this counter is looking interesting.  Could we see a breakout soon? In case of a breakout, we could see a retest of 21c, the high of 16 Jun.

Healthway Medical: Going down?

What is happening to Healthway Medical's share price, some might ask?  Since 5 July, price has only closed above the declining 20dMA twice. In the last five sessions, share price closed at 18.5c, the immediate support. The question on shareholders' minds is whether this support level will hold.  Will it? I don't know. What an answer, right?  Well, TA cannot tell us things like that. It's always a question of probability.  So, might it?  Let us examine some technical indicators.

The declining 20dMA suggests a short term downtrend.  Price closing at 18.5c for five sessions in a row is bearish but note the volume.  It has been thinning as price declined.  A low volume pull back?  Good for the bulls. The MFI has been forming higher lows and the OBV has declined ever so slightly.  Both indicators suggest that there is some underlying support. Again, good for the bulls.  So, 18.5c immediate support might hold.

What if 18.5c breaks?  Well, the longer term MAs are still rising.  The 50dMA should provide some support at 18c in case 18.5c cracks.  Unless there is a significant expansion in volume with any selling down, the 100dMA which is currently at 17c is unlikely to be tested as a support in the immediate future.

Related post:
Charts in brief: 16 Jul 10 (Part 2).

STI gains 0.4% to 2,979.38 at closing. Shares on the measure trade at 14.4 times estimated earnings, compared with about 17.5 times at the beginning of the year, according to Bloomberg data.
Tuesday, 27 July 2010

© 2010 - The Edge Singapore

Charts in brief: 16 Jul 10 (Part 2).

FSL Trust: 42c seems like a difficult resistance to overcome at this point in time. This is gap resistance and resistance provided by the declining 50dMA at the same time. RSI has also moved higher up into the overbought region while we see a sell signal on the MACD histogram.  Volume has been reducing as price moved higher. Without an expansion in volume as price moves higher, it is unlikely that 42c could be taken out in the next session. Unless there is some positive newsflow soon, chances of a pullback in price are higher. With all the higher lows formed in the MFI and RSI, the momentum oscillators are clearly uptrending and I expect any pullback to find initial support at 40c.

Genting SP: First touched on 29 Jun, $1.20 has proven to be a tough nut to crack. Volume has been reducing since that day as price stayed above the 20dMA. If we look purely at the 20dMA, the short term uptrend seems to be intact. However, if we look at the MACD, we see a bearish crossover with the signal line on 2 Jul and since then the MACD has been declining beneath the signal line. MFI, RSI and OBV have all flatlined.  There is clearly no trend where these indicators are concerned.  Pay attention to the 20dMA which should be at $1.17 in the next session or so.  If this is breached, price could move lower rapidly.

Healthway Medical: Since price touched a high of 21c on 16 Jun, the MFI has been in decline.  This suggests a weakening demand. However, we do not see a similar decline in the OBV.  In fact, the OBV has gone up which suggests that there is more accumulation than distribution. There is some underlying support and even though demand has weakened, there is little selling pressure.  Immediate support is at 18.5c.

K-REIT: A very nice up day with a very nice white candle as volume more than doubled from the previous session.  Price closed at $1.22, the high of 11 and 12 Jan.  if momentum keeps up and price action goes parabolic, I won't be surprised if we see $1.34 (161.8% Fibo line). At this point in time, it is still a fantasy.

Related posts:
FSL Trust: The skies are clearing up.

Charts in brief: 2 Jul 10.

AIMS AMP Cap Ind REIT: Volume rose today as more shares changed hands at the 21.5c support.  MFI declined sharply as short term demand seems to have disappeared. In spite of this, there is no sharp decline in the OBV.  Instead, it is flattish which suggests a lack of heavy distribution activity. From the high achieved on 3 Jun, price seems to be doing a low volume pullback to support.  If 21.5c support should break, I would be happy to buy more at the long term support of 20.5c.  Based on FA, I think that is a very attractive price. TA is more mutable and needs to be looked at again at that point in time.

According to DTZ Research, the improving Singapore economy has caused industrial rents in Singapore to rise for the first time after quarters of decline since Q3 2008.

DTZ’s latest report on industrial property stated, “Average monthly gross rents of first-storey private industrial space edged up 2.6% quarter-on-quarter (QOQ) to $2.00 per sq ft and 3.2% QOQ to $1.60 per sq ft for upper-storey space per month. Since the height in Q3 2008, average monthly gross rents of first-storey and upper-storey private industrial space have fallen 14.9% and 22.0% respectively.”

However, the research consultancy reported that “rents for hi-tech industrial properties, which include business park and science park space, were unchanged at $3.15 per sq per month in Q2 2010.”Article here.

Healthway Medical: Clinging on to support at 19c while forming a gravestone doji is ominous. The rising 20dMA is exactly at 19c now.  Will it push the price higher in the next session or will it fail as support? The MFI, which accounts for price and volume and is a measure of demand is clearly in decline.  The OBV shows the sharpest drop in three weeks, suggesting that distribution is heightening. MACD continues to decline below the signal line. It is obvious that upward momentum and demand have both weakened. If 19c breaks as support, next support is not far away at 18.5c which was a resistance formed in March as price tried to advance higher then.

SPH: A friend asked me if he should sell his SPH shares today. Let's look at the chart.  With today's expansion in volume on a white candle day as price hit a high of $3.88 before closing at $3.85, SPH looks like it might be able to go higher. MFI has been forming higher lows, suggesting rising demand. RSI has been rising as well.  The MACD is still in positive territory.  In short, SPH is seeing some underlying strength. $3.88 is the resistance to watch.  If it breaks convincingly, I see an eventual target price of $4.08. I would be happy to sell more of my remaining shares in SPH then.

Related post:

SPH: Reading the lines.

Charts in brief: 28 Jun 10.

CapitaMalls Asia: This is hanging on to support at $2.14 but barely so as price touched a low of $2.11 today.  The 20dMA which is providing support at $2.14 seems to be flattening. More significantly, I would like to draw attention to the fact that closing at $2.14 today is different from closing at $2.14 last Friday because the uptrend is now broken.  MFI continues its decline and the MACD looks set for a bearish crossover with the signal line.  I would not go long at $2.14 now.  The downside risk is too high.

Golden Agriculture: An inverted white hammer on lower volume. Momentum oscillators are flattish.  There is just no oomph in the upward movement in price today as it touched a high of  54c before closing at 53c.  Immediate support at 52c as provided by the 20dMA.

Healthway Medical: Its price is showing resilience as trading volume declined. 19c has been established as the immediate support. OBV is flattish and there is no sign of distribution. However, MFI and RSI are both hugging the borders of their respective overbought zones.  Might this exert some downward pressure on price or is this counter just doing a correction using time and would resume its uptrend once the 20dMA catches up?

SPH: This counter has been delivering pleasant surprises lately. Today, it closed at $3.88.  This effectively overcame the declining 50dMA as resistance. $3.88 was the eventual target of a mini double bottom I identified some time back.  I also divested some shares at this price not too long ago. The move up today was not accompanied by an expansion in volume.  So, I am doubtful about its strength.  However, the MFI and RSI are both rising and their uptrends are intact.  Momentum is good and if the price continues rising to hit certain Fibo lines, I might sell more of my remaining shares.

Related posts:

CapitaMalls Asia: Weakening technicals.

Golden Agriculture: Inverted black hammer.

SPH: Reading the lines.

Charts in brief: 23 Jun 10.

AIMS AMP Capital Industrial REIT: It is hugging the support at 21.5c. MFI continues to descend and has gone below 50%.  I said earlier that if the price stays at or above 21.5c while MFI descends, it is good news for the bulls. This analysis is still valid.  The Bollinger bands look like they are in the early stages of tightening.  A narrowing of the bands signify reduced volatility before a possible sharp movement either way.  With the increased accumulation activity as suggested by the rising OBV, it is likely that this eventual movement is going to be up.

CapitaMalls Asia: I would be very cautious and not go long here. If we look at the daily chart, the price action has closed above the 100dMA. Even though it has done so on lower volume, bulls may cheer. However, if we look at the 100dEMA instead which gives greater weightage to recent price activity, we see a different picture and realise that resistance really has not been taken out yet and that is at $2.22.

Golden Agriculture: MFI seems to be in the early stages of forming lower highs and lower lows. Positive buying momentum is failing. The declining 50dMA is providing resistance at 54.5c now which is where the price closed today. Immediate support at 53.5c but a stronger support is at 51.5c where the 20dMA has just made a golden cross with the 200dMA.

Healthway Medical: Price has very clearly detached from the upper Bollinger band. Forming another doji at this stage suggests that it is most likely that a reversal is on the cards.  MFI is falling from overbought territory and the MACD is turning down towards the signal line. All signs of technical weakness. Initial support is at 18.5c, a resistance level which failed to be taken out earlier this year in March.

Problems in over-leveraged developed economies will eventually reach Asia, including Singapore, either via reduced Asian exports or shock to global financial system, says CIMB, according to Dow Jones....Against this backdrop, house advocates overweight strategy on defensive plays like REITs, as well as proxies to Asia consumption theme, such as Genting Singapore (G13.SG), Raffles Medical Group (R01.SG).

Go for defensive, consumption stocks in Singapore, says CIMB
Wednesday, 23 June 2010

© 2010 - The Edge Singapore

CDL Hospitality Trust (CDREIT SP), the hotel operator partly-owned by City Developments (CIT SP), tumbled 6.4% to $1.77, its biggest decline since March 30. The company said it raised net proceeds of $196.4 million, selling shares at $1.71 each, the lower-end of the price range for the share placement.

STI little changed at 2,871.05 at the closing
Wednesday, 23 June 2010

© 2010 - The Edge Singapore

Related post:
Charts in brief: 22 Jun 10.